Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 66,000 shares, a growth of 67.1% from the October 31st total of 39,500 shares. Currently, 9.7% of the shares of the stock are short sold. Based on an average daily volume of 58,000 shares, the short-interest ratio is currently 1.1 days.

Cadrenal Therapeutics Stock Performance

Shares of Cadrenal Therapeutics stock opened at $15.19 on Friday. The stock’s 50 day moving average is $14.66. The stock has a market capitalization of $25.20 million, a P/E ratio of -2.27 and a beta of 1.52. Cadrenal Therapeutics has a one year low of $5.40 and a one year high of $32.55.

Analyst Ratings Changes

Separately, HC Wainwright upped their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.